Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
Drawing from its massive consumer genetic dataset and longitudinal survey data, 23andMe is searching for genetic features that might influence the severity of SARS-CoV-2 infections.
Using data for more than half a million individuals, researchers identified 449 refractive area-related loci, including 336 sites not linked to the eye condition in the past.
Some of the market's most influential voices, including Kári Stefánsson and Linda Avey, believe that consumer genomics is not on the way out but rather experiencing a period of transition.
The FDA has been prodding labs performing pharmacogenetic testing, and software firms providing reports from such testing, to undergo regulatory review.
Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.
